Enveric has created many novel molecules with unique receptor binding profiles and pharmacokinetic properties.

The molecules represent an opportunity for pipeline development and access to novel, protected compounds in important medical markets.

For Enveric, out-licensing Psybrary™ assets is an opportunity to diversify risk while capitalizing on and retaining potential milestone payments and royalty revenue across multiple drug candidates and markets.